Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Novelion Therapeutics Inc (NVLN.TO)

Novelion Therapeutics Inc (NVLN.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Novelion Therapeutics Inc c/o Norton Rose Fulbright, 510 West Georgia Street Suite 1800 Vancouver BC V6B 0M3 CAN

P: 877-764-3131

Description:

Novelion Therapeutics Inc is a biopharmaceutical company. It is engaged in developing patient care facility and providing services for people suffering from rare diseases like lipodystrophy, leber congenital amaurosis, and retinitis pigmentosa. Novelion, Aegerion, JUXTAPID, LOJUXTA, MYALEPT and MYALEPTA are the registered trademarks of the company.

Key Statistics

Overview:

Market Capitalization, $K 247,123
Shares Outstanding, K 18,932
Annual Sales, $ 0 K
Annual Net Income, $ 0 K
60-Month Beta -0.39
% of Insider Shareholders 0.77%
% of Institutional Shareholders 85.94%

Growth:

1-Year Return 1.14%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth -20.31%

Per-Share Information:

Latest Earnings Date N/A
Earnings Per Share ttm -6.06
Most Recent Dividend 19.576 on 06/28/13
Next Ex-Dividends Date 06/28/13
Dividend Payable Date 06/27/13
Dividend Payout Ratio 0.00%
Most Recent Split 1-5 on 12/21/16

NVLN.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % N/A
Return-on-Assets % -30.64%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Book 1.86
Book Value/Share N/A
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar